JLL appoints new head of Life Sciences for UK Project & Development Services (PDS)

JLL has appointed Richard Cairnes to lead its Project & Development Services (PDS) team in Life Sciences in the UK. In his new role, Richard will lead the national team of experts across a wide variety of disciplines to deliver lasting value from built assets to JLL’s science and technology clients.

Richard brings a breadth of experience to the team, joining from Currie & Brown, construction and cost management consultants where he was responsible for the London and Southeast Pharmaceutical and Life Science team providing leadership and management. Throughout this tenure, he had managed projects and programmes in secure and controlled environments in the pharmaceutical and life science sectors including high containment laboratories, clean rooms, GMP and research and development. His key client work and experience include central government bodies and departments, research institutes, pharmaceutical and biotechnology companies and higher education universities.

Richard is also a current and active Committee Member of the Association for Project Management (APM) Programme Management Specific Interest Group (SIG), where he enthusiastically promotes project and programme management awareness, provides thought leadership on appropriate subject matter topics, encourages collaboration, provides knowledge sharing and transfer using appropriate tools, processes and areas of good practice and champions a programmatic approach to delivery.

UK Head of Project Management, Life Sciences at JLL, Richard Cairnes, “I’m really excited to embark on this new career journey at JLL, it is a fantastic opportunity to work with Chris Walters  and the wider JLL Life Science teams to further strengthen JLL’s PDS offering externally in this sector and to help bring the best results to our clients.”

Nick Winter, Head of UK Project & Development Services UK at JLL added, “Richard’s outstanding track record in delivering projects in this sector will enhance our current strengths to unlock future growth within the Life Sciences sector in the UK.”